Kane Biotech Inc KNBIF

Primary Symbol: V.KNE

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by francoisl13on May 13, 2024 10:15am

97 Views

Post# 36036683

SAWC (Orlando,FL) May 2024

Interesting piece of info found on the Progenacare LinkedIN page;
''We will also be presenting new clinical and scientific data on these products at the podium and in multiple posters, and participating in the Hands On Skills Lab''
These 'products' mentioned in the post are; human keratin matrix (Progenacare main product) and Revyve (Kane) so, it looks like new clinical and scientific data are now available for Revyve...this could be another interesting week.
GLTA

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China